- NewsCategory：
- All Company news Industry news
common105One result
-
1031
Gotham Therapeutics Establisheβ"δs Advanced Oncology Profiling C÷•✘↔ascade with ProQinase to Progress♥∑ α its Portfolio of Epitransc©≤®riptomic Drug Candidates
Gotham Therapeutics Establishes Advanced Oncology£ ☆÷ Profiling Cascade with ProQinase to Progress itsσ★↔ Portfolio of Epitranscriptomic D♠↔rug CandidatesWEDNESDA®φ♥Y, OCTOBER 30, 2019Gotham Th×♠erapeutics, a biotechnology com÷'pany developing a no£ vel drug class targeting ¶₩§'RNA-modifying protei₽Ωns, and ProQinase, an early stage dr≥₩ug-discovery company, recen¶πtly acquired by Malvern/PA-based Reaction Biologyφ₽α✘ Corp., today announced that they have establis∞₹hed an array of advanced biochemicaπλ$l and cellular assays to ≤↕∏characterize epitrans"∞₽×criptomic-directed compounds.“Es♥σ±tablishing tailored target engagement, cell bio§↕logy, phenotypic, and in-vivo as>≠φsays to evaluate compounds originatiα<>ng from our three most advanced epitranscr¥±"≤iptomic programs in parallel is a ♠φcrucial next step to develop our broad pipe×≈★line towards the clinic,” said Dr. Ge'≠←rhard Müller, Chief Scientific Officer 啧of Gotham Therapeutics. “Byδ≈ pursuing the full range o≥₹↕f the reader-writer-eraser continuum, we∞δ are able to focus on targets with the most com♦ φpelling links to disease and advance thδσ♦☆ose programs in tandem.”“Combining our high profi→≥ciency in providing customized so©∑lutions as early stage drug÷×-discovery services, including tailor-$★δmade biochemical and cell-based assays, with<π•' Gotham’s expertise in epitranscriptomλ™ ics, we were able to establish σ≤in a very short time a s&♠∏∏et of customized enzymatic and celφ↑lular assays for compouγ nds addressing three different mRNA-mo" '♣difying targets,” said Dr. S÷σ↓ebastian Dempe, Chief Executi&≤φve Officer of ProQinas☆≠↑e. “We look forward to suppo¶ ₹βrting Gotham as the company advances its program♠©αs into lead optimization and to conti→∞£&nued work with the Gotham team assisting t✔$∞he company to advance i>$ts broad pipeline in a time-effective manne✔σr.”In addition to establishing a tailor-m€✔★ade profiling cascade for compounds from its thre $✘≤e most advanced programs, Gotham has alsoδ∑₩♥ made progress in strengthening it✘¥s drug discovery engine and developingδΩ its candidate base. Gotham¥±↑δ previously completed the gene-to-lead phase fo✘φr its drug discovery project↔÷ targeting the METTL¥∑3/METTL14 complex and establishe₩♦d a robust discovery process as a p✘€$latform for future projects. The company has als÷®∏o generated a librar>¥λy of high-quality compounds tailor-made∏≈ for accelerated hit ®$&generation and hit-to&"✘α-lead expansion against large par₩✔ts of the epitranscriptomic target s±♦pace. This library includesγ♦α a collection of over 2,000 analogues c♥β∞✘overing over 80 distinct chem★♠→otypes that will be used <$✔¶to further accelerate Gotham’s dr₩✔ug discovery efforts as it expands it↓≠ s pipeline.The original link:h←→•ttps://www.pharmafocusasia.c↔ 'om/news/gotham-therapeu¶∏ tics-establishes-advanced-oncology-pε↔rofiling-cascade-with-proqinase-to-progres™®s-its-portfolio-of-epi↕←σ'transcriptomic-drug-candidates2 019 Asia-pacific pharma IP Leader SΩ↑$ummit: http://en.zenseegroup.com/££®πp/510934/will be held✘π in Beijing on No®✔vember 14-15, and will attract more than 50'∑≈0 industry experts from d≠↕←omestic and foreign pharmaceutical coδΩ§↑mpanies, biotechnology companies, governments, as★♦$sociations, law firms, intellectual propert☆<$y agents and other coπλ >mpanies to attend.Official ×π×registration and cons÷↓♥ultation channels:Contact：ε>•AnnPhone: 021-65650305Email：Marketing@zenseegσ roup.comhttp://en.zense∞<egroup.com/p/510934 -
1030
Gilead and Glympse Bio Anα↕nounce Strategic Collaboration for Use of Biom∞∑arker Technology in NASH Clinica•♠>l Development
Gilead and Glympse Bio Announc∞→§e Strategic Collaboration for Use of BiomaΩ©rker Technology in NASH Clinical Dev♣☆™✘elopmentTUESDAY, OCTOBER 29, 201≈•$9Gilead Sciences Inc. and Glympse Bio, Inc., tod€£ay announced that the compδε≤'anies have entered into a strategic collaborat↕λion in nonalcoholic steato≠&πhepatitis (NASH) clinical development. Glympse →§Bio’s proprietary synthetic biomarkers – bioeng↑±₩ineered to identify stage and progression of dise★±✔ase as well as early de" tection of treatment response – will be used to ≤'determine clinical trial participants'λ ’ stage of disease at initial ♠ ↕screening and to determine €§responses to study treatment in∏¥ε Gilead’s NASH clinical program.“We are excite×$d about the opportunity to partner w§ ith Glympse Bio to hel₩ >↔p inform our NASH development program,” said ₹'αMani Subramanian, MD,↑δ→ PhD Senior Vice Presid☆φent, Liver Diseases, Gilead Sβ¶$ciences. “By utilizing this innovative t→÷echnology, we hope to better characteriz∞β♦ e this complex disease and improve our understπ÷∞anding of how our compounds ↑impact disease progression.”Glympse Bio’s∞α↕ proprietary technology, Glympse ₩Inside™, combines synthetic biomarkers with mac" ★£hine learning approaches to ide αntify the stage and mon€±itor progression of important, coελ÷mplex diseases such as cance§≤r, fibrosis, inflammation, and infe δ☆ctions, in real time.“We are very excited a→€bout partnering with Gilead, ×σa leader in drug development, to help ☆'€'drive earlier and more favorable o÷₩utcomes for patients,φ☆” said Caroline J Loew, δ™✔President and CEO, Glympse Bio. “Gileဧad’s commitment to developing innovati₽≠ve medicines in areas of high unmet<¥♦< medical need aligns witΩ₹♠h our mission of transforming disease detection ×" and measuring treatment r'Ω"esponse, all with the Ωgoal of helping improve the ∞ε×>lives of patients.”information sou∞↑rce:pharma focus AsiaThe origin®πδδal link:https:https:https://www.pharmafo•★♠cusasia.com/news/gilea§♥♦d-and-glympse-bio-announce±×-strategic-collaboration-for-use-of-biomarke§δr-technology-in-nash-clinic©☆★al-development2019 Asia-pacific pharma ₽σ≠≥IP Leader Summit:http://en.₹zenseegroup.com/p/510934/$★ will be held in&nbs₽λp;Beijing on Novem©∏®£ber 14-15, and will attract more tha♥"≈n 500 industry experts from domestic and foreig×←n pharmaceutical companies, b €iotechnology companies, government♣÷™s, associations, law πφfirms, intellectual proper&±ty agents and other companies to "attend.Official registration and consultati♠on channels:Contact：AnnPhone: 021-656←₩50305Email：Marketing@zenseegroup.comhttp://δα←♦en.zenseegroup.com/p</510934 -
1029
HistoIndex Announces γαGlobal Partnerships To Expand AI-Based Dig≈÷ital Pathology Platform
HistoIndex Announces Glob₽•al Partnerships To Ex✔δ✔pand AI-Based Digital Pathology PlatformM€"ONDAY, OCTOBER 28, 2019H∑♦£istoIndex announces ∑←the expansion of its AI-based digital path≥ φ↕ology platform towards≠δ∑ large-scale NASH preclinical φ<γprograms for pharmaceutiδγcal and biotech companies to achieve quant↕∞®♠ifiable and reproducible data on th∞erapeutic responses in NASH animal models, and to↔↕±≤ aid CROs as well as research"ε agencies in validating new models mimicking∏≠φ the NASH disease.Pu€blished preclinical studies σΩhave demonstrated the use of HistoIndex's fully qΩ↕γγuantifiable Second Harmonic Generatio ←×n (SHG) technology as a highly accurate ₽≈×™stain-free method tha☆♥£ t can monitor the efficacy of various the♠£ε>rapeutic agents, by quantify<πβ↑ing more than 450 NASH-associated param$ eters in fibrosis, inflammation, ballooning and s₩✘₩teatosis. The information of these NASγσH-associated parameters gathered from the en>φtire liver tissue, provides comprehensive insig₽↔♥★hts on the mechanism of action of the therap>§eutic agent. As a drug discovery tool, Hi±✔¶λstoIndex's SHG-enabled digital pathology platσγλ♠form will allow pharmaceutical$$ σ and biotech companies to select promis ™Ω•ing lead candidates for further optimization a ♦↑₹nd make informed decisions in the m♣÷≠•anagement of their NASH drug development pipelin♥♣♥♦e.In addition to ongoing NASH"♦ clinical trials, HistoIndex is curren¥↔αtly involved in multiple preclinical studies, mos©☆εt of which are conducted by major pharmaceuti&±cal and biotech companies, medical un ± σiversities, CROs and research agencies. Notably, ≠™£≠HistoIndex has recently entered into a collab♥ π∞oration with the A*STAR©δ↑♥'s Genome Institute of Singapore (GIS) t₹Ω∞o validate their in vivo and in vitro NASαβH models based on Asian-centric clin™λ✘ical data. Says Profes♦γsor Patrick Tan, Executive Director of the Genom e Institute of Singapore®↔♥ (GIS), "At GIS, we cond€πuct our preclinical studieδαs on fatty liver involving data ¥εfrom animal models based on patient-derived δ$$transcriptomic data. This has a high translat☆÷✔ional potential as it helps us to pinpoint newπ₽↔ therapeutic targets and their va≠δ✔lidation. Therefore, using a fully quantit∞←ative, reliable and object★∑™ive pathological evaluation sucΩ₹•±h as HistoIndex's AI-based digital pathφ∏ology platform is essentiaσl to the success of our ef&π∞forts in therapeutic target d₹≠>λiscovery."HistoIndex is®γ also a partner with globally-renowned CRO, WuXiπ©"> Apptec, in advancing their NASH preclinical prog♦<♦rams with advanced R&D and smart≈↓↕ imaging analysis capabiliti ∑®es. Published study "✔≠✘data will be available f≤$γor discussions during networking opportunitie€ s throughout AASLD's The Liver Meeting® in•♦ November 2019. "We are v≥$ε"ery excited to extend our AI-based SHG platfor¥←σεm to preclinical studies to help companies witφ✘h drug discovery programs select promising lead c ∞andidates for further ¥≤↔optimization and subsequent clinical develop•$ment," says Dr Poon Thong Yuen, C' hief Executive Officer o≠≤f HistoIndex. "Our SHG image←'λ> analysis platform has already been usedΩ↕÷ to analyze the efficacy of a serβ&ies of promising drug candidates for N☆÷<↑ASH within various animal models commonly-used byα≈ the industry, and we believe these preclinicalδ∑ partnerships will help drive the adopt∞₩ion of our platform significantly₹♣&↕."information source:pha®♠¥βrma focus AsiaThe original link:https:https://γ"www.pharmafocusasia.com/news/histoind φ÷ex-announces-global-partnerships-to-expand-ai-λ★based-digital-pathology-platform2019✘♠♦ Asia-pacific pharma IP Leader Summit: h>φ♥↑ttp://en.zenseegroup.com/p/510934/will b ¶ ≥e held in Beiji♦↑δ₽ng on November 14-15, an$δβ♠d will attract more than 500 industr←"×y experts from domestic and foreign pharmace✔™βutical companies, biotechnology companieσ€δ±s, governments, associations, law firms, intel<↔lectual property agents and ot®☆her companies to attend.Official registration a≠ nd consultation channels:Contact：AnnPhone: 021-65★ ®650305Email：Marketing@zenseegroup.co→±mhttp://en.zenseegroup.com/p/510€₽♦934 -
1028
AVROBIO Receives Orphan-Drug Designatio©Ωn from the U.S. FDA for AVR‑RD‑02 for the ↕ Treatment of Gaucher Dis§≤↔ease
AVROBIO Receives Orphan-Drug Designatiσεon from the U.S. FDA for AVR‑RD‑02 fo" ₩r the Treatment of G☆☆♠aucher DiseaseFRIDAY, OCTOBER 25, 2019AVROBIO, Inβ®c., today announced that the U.S. Food an♥★"¶d Drug Administration (FD"₽∞A) has granted orphan-drug designaδφαtion for the Company’s investigati↑©onal gene therapy, AVR-RD-02, ✔σΩfor the treatment of Gauεcher disease. AVR-RD-02 ₽₽♥consists of the patien ε←t’s own hematopoietic stem cell♦πs, genetically modified to express glucocereb©φ© rosidase (GCase), the enzyme that is de★©&ficient in Gaucher disease. Th©© e Company is activel↑πy recruiting in Canada for "≈its Phase 1/2 clinical trial of AVR-RD-02, "'β→which seeks to evaluate th₹↑<&e safety and efficacy of the therapy in pa>∑tients with Type 1 Gaucher disease.“U×€₩→nder the existing standard of care, pati™∑∏ents with Gaucher disease are •∑↔bound to a lifelong infusion schedule of e"€¶nzyme replacement therapies, and stilΩ ♣l experience painful and progressive sympto'×ms such as debilitating musculoskeletal p' ain and fatigue,” said Birgitte Volck⮶©, MD, PhD, President of Research a¶<✘§nd Development at AVROBIO£. “Orphan-drug designatioα₩n recognizes the unm¶≠•↓et need of populations with rare diseases like"®✔ Gaucher where AVROBIO strive♥♦☆s to transform lives★ ↔ by addressing the underlying cause of ♣'the disease with a single dose of gene therαπ÷apy.”Orphan-drug designation ↕∏ is granted by the FDA to drugs and biologics wh ♦✘ich are intended for ∑∑the safe and effective tre± atment, diagnosis or prevention of rare ≠γ¥diseases or conditions that ≤®✘•affect fewer than 200,000 people in the Uniφ₩ted States. Orphan-dδ$¥λrug designation provides certain inc>↔δentives, which may include tax credit₹≤s towards the cost of clinical trial∞∏s and prescription drug ♠Ω₩↕user fee waivers.information source:←< ↑pharma focus AsiaThe origi∑↔÷εnal link:https:https:/§☆×/www.pharmafocusasia.αλ™com/news/avrobio-receives-orphan-drug-∞≤αdesignation-from-the-us-fda•♣-for-avrrd02-for-the-treatment-of-gaucher-disea↓"γπse2019 Asia-pacific ®₹¥pharma IP Leader Summit: http://en.zenseegro'Ω•'up.com/p/510934/will be held in&n₩✘bsp;Beijing on&n✘∏ bsp;November 14-15, and will attra♠♠≠₩ct more than 500 industry experts from do✔±₩mestic and foreign pharmaceutic±∏al companies, biotechnology compan±$ies, governments, associations, law firms,↕€ intellectual property agents and othe"ε'↓r companies to attend.Offi≠≥≥∞cial registration and consultation channels±✔:Contact：AnnPhone: 021-65650305E≈♦mail：Marketing@zenseegroup.comhttp://en.ze>©♥nseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neur♦ε¥oinflammation-Targeted Pipeli₽→ne Through Acquisition of Smith Therape↓↔☆✔utics
FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a b$★∑✘iopharmaceutical company developing thα←♣εerapeutics to extend brain health, today announceε✘φ$d the acquisition of Smith∞ε Therapeutics, a private biophar×π≈maceutical company with a shared goal"δ of targeting neuroinflam©≈×mation to treat neurodegenerative ₹σ 'disease. Smith Therapeutics’ Founder and C¥×πhief Executive Officer Philip Ashton-Rickardt,σ£ Ph.D., has joined the senior leadership <®₹×team at AZTherapies as Senior Vice Pre'™sident of Immunology. Fin≥ ←ancial terms of the acquisition w±£₽ere not disclosed.Smith Therapeutics’ proprie€↕tary research platform focuses on the us♠&♦e of modified T cells to restore a hea≈α>lthy balance of inflammatory an♥®&d regulatory cells in the brain. To date, Smit↕"αh has successfully engineeδ♥red immunosuppressive ←÷♠T regulatory (Treg) cells with Chimeric Antigeα₽αn Receptors (CARs) targeting brain glial cells. ©©≈Previous research has demonstrated theφ• ♦ ability of Tregs to dampen microglial act±≈ivity and reduce neuroinflammation in m∑♦odels of neurodegeneration, sugge <★sting their potential>δ¶✔ utility in the treatment of diseases inclu₽' ding Progressive Supranuclear Palsy (PSP ±), Alzheimer’s disease, Parkinson’s disease, ♣∞♦Huntington’s disease, Amyotrop•♣hic Lateral Sclerosis (ALS), ±± ∑and others.“This acquisition repr•÷esents a meaningful step forward for us'&€ as we continue to streng£♥€then our leadership position in§"₽↓ the development of t←λ'herapies targeting neuroinflammat★€™¶ion to stop or slow the progression→>βλ of neurodegenerativ♣ e diseases,” said David R. Elmaleh, Ph.D., ↕πFounder, CEO, and Chairman of AZTherapie♦∏s. “We are excited to be working with •§Philip as we add this cutting-edge technolog←Ωy to our portfolio of innovative programs. An→¶₽✔ esteemed immunologisΩ≤£t and inventor of the techno>®δlogy, Philip brings unparalleled ₽☆expertise to the company and we look forward to a™Ω€dvancing this CAR-Treg program further int♦£♠∏o IND-enabling studies and into c☆↕πlinical development as rapidly as possible.©©♣¶”Dr. Ashton-Rickardt commented on the acquisition☆∞•₽ and his appointment: “Our shared rationaε•☆le of targeting neuroinflammation as the root ≠©cause of neurodegenerati∏≈ve disease makes this acquisition a gΩπ®σreat strategic fit fo↓¥€r us. With AZTherapies’ expertise in drug de ¶velopment and clinical tr•↓∑ial execution, we believe that togetherπ☆, we are well positio ≈αδned to advance our CAR-Treg technology and fu÷∏ ndamentally change neurodegenerative disease±£ progression.”Prior to launchiα±ng Smith Therapeutics in 2017, Dr. Ashton-RicΩ©kardt was Chair in Immunology↔♣ at Imperial College London, Visitingφ♦ Professor, Brigham and Women’s Hospital, Harvard✔'Ω Medical School, and Associate Professor in t♣∏he Department of Pathology at the ∞↔University of Chicago. His work has been recogniγzed by his peers through t✔₹₽he award of tenure from The University of Ch✔✔icago and by his fellow citizeπns as a recipient of the Early Car∏ eer Award for Scientists an≈≈✘d Engineers from President Bill Clinton. H£ε$±e has published more than 65 pe₹ σer-reviewed papers in more←• than 30 academic jou♦♦λ☆rnals (including Cell, Science, Immunity, aφ☆nd Nature Immunology),®"£π has served as an editor for several acad®≥">emic journals, and has been a member of grant ≈∑↓review boards globally. Dr. Ashton-Ri↔₩ckardt received a B.Sc. in Bioche" ≠mistry from the University of Londo®σ>n, King’s College with ho₩¥→↔nors, a Ph.D. in Molecular Bi÷®≤<ology from the Univer&&sity of Edinburgh, and completed pos t-doctoral work at the U≤↑niversity of Edinburgh a✔✘nd the Massachusetts Institu←te of Technology in Molecular Biol®≠©✘ogy and Molecular Immunology, respectively.infγ∑ormation source:pharma focus As±≥♠•iaThe original link:https:https://<✘∞φwww.pharmafocusasia.c✔β≠→om/news/aztherapies-strengthens-n•★☆γeuroinflammation-targeted-pipeline-th★≥rough-acquisition-of-smith-therap€♠≠eutics2019 Asia-pacific pharma IP Lea↑ ←der Summit: http://en.z₽€•βenseegroup.com/p/510934/will be held in&nφ€←bsp;Beijing on ✔εNovember 14-15, and will attrac♣α♥t more than 500 industry experts from do♠≈mestic and foreign pharmaceutica→£×l companies, biotechnolo≤✔gy companies, governments, associa∞φβ tions, law firms, in₽∑♠'tellectual property agent"αs and other companies to a↔≈↑×ttend.Official registration and φδ¶consultation channels:C₹•ontact：AnnPhone: 021-65650305E≥π® mail：Marketing@zenseegroup.comhttp:/δ↕"/en.zenseegroup.com/p/510934
Contact Us
Zensee_Daystar onlin∏ ↓e
© 2011-2016